• The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 24. doi: 10.1080/14737167.2023.2169136. Epub ahead of print.
    • Financial toxicity in BRCA1 and BRCA2 carriers.
    • Proussaloglou EM, Rosenthal AE, Raker CA, Wilbur JS, Stuckey AR, Robison KM.
    • Gynecol Oncol. 2023 Jan 24;170:160-166. doi: 10.1016/j.ygyno.2023.01.007. Epub ahead of print.
    • Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 17. doi: 10.1080/14737167.2023.2169137. Epub ahead of print.
    • The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 13. doi: 10.1080/14737167.2023.2169135. Epub ahead of print.
    • Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer.
    • Jang J, Kim Y, Kim JH, Cho SM, Lee KA.
    • Ann Lab Med. 2023 Jan 1;43(1):73-81. doi: 10.3343/alm.2023.43.1.73.

    Related:

    Commentary:

    Cost-effective BRCA Testing in Advanced Ovarian Cancer.

    • All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    • Wu HL, Luo ZY, He ZL, Gong Y, Mo M, Ming WK, Liu GY.
    • Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111-y. Epub ahead of print.
    • Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    • Ding H, He C, Tong Y, Fang Q, Mi X, Chen L, Xin W, Fang L.
    • PLoS One. 2022 Dec 15;17(12):e0279286. doi: 10.1371/journal.pone.0279286.
    • Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
    • Michaelson-Cohen R, Cohen MJ, Cohen C, Greenberg D, Shmueli A, Lieberman S, Tomer A, Levy-Lahad E, Lahad A.
    • Cancers (Basel). 2022 Dec 12;14(24):6113. doi: 10.3390/cancers14246113.
    • A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.
    • Teppala S, Hodgkinson B, Hayes S, Scuffham P, Tuffaha H.
    • J Med Econ. 2022 Nov 25:1-38. doi: 10.1080/13696998.2022.2152233. Epub ahead of print.
    • Implementation of multigene panel testing for breast and ovarian cancer in South Africa: a step towards excellence in Oncology for the public sector.
    • Van Der Merwe NC, Ntaita KS, Stofberg H, Combrink HM, Oosthuizen J, Kotze MJ.
    • Front Oncol. 2022 Nov 8;12:938561. doi: 10.3389/fonc.2022.938561.
    • From the patient to the population: Use of genomics for population screening.
    • Mighton C, Shickh S, Aguda V, Krishnapillai S, Adi-Wauran E, Bombard Y.
    • Front Genet. 2022 Oct 24;13:893832. doi: 10.3389/fgene.2022.893832.
    • Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
    • Kwon JS, Tinker AV, Santos J, Compton K, Sun S, Schrader KA, Karsan A.
    • JCO Precis Oncol. 2022 Oct [20];6:e2200033. doi: 10.1200/PO.22.00033.
    • Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    • Levine MD, Barrington DA, Hampel H, Goodfellow PJ, Cohn DE.
    • Gynecol Oncol. 2022 Sep;166(3):538-542. doi: 10.1016/j.ygyno.2022.07.016. Epub 2022 Jul 21.
    • Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
    • Peters MLB, Eckel A, Lietz A, Seguin C, Mueller P, Hur C, Pandharipande PV.
    • Pancreatology. 2022 Sep;22(6):760-769. doi: 10.1016/j.pan.2022.05.003. Epub 2022 May 31.
    • Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review.
    • Dixon P, Keeney E, Taylor JC, Wordsworth S, Martin RM.
    • Genet Med. 2022 Aug;24(8):1604-1617. doi: 10.1016/j.gim.2022.04.020. Epub 2022 May 16.
    • Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.
    • Lourenção M, Simões Correa Galendi J, Galvão HCR, Antoniazzi AP, Grasel RS, Carvalho AL, Mauad EC, de Oliveira JHC, Reis RM, Mandrik O, Palmero EI.
    • Front Oncol. 2022 Jul 11;12:951310. doi: 10.3389/fonc.2022.951310.
    • Evaluating Costs Associated With Genetic Counseling Among Commercially Insured US Patients With Cancer From 2013 to 2019.
    • Roberson ML, Padi-Adjirackor NA, Hooker G, Pal T.
    • JAMA Health Forum. 2022 Jul 29 [eCollection 2022 Jul];3(7):e222260. doi: 10.1001/jamahealthforum.2022.2260.

    Related:

    Research news: Genetic Counseling for Cancer Often Costs Patients Nothing. (Medscape Oncology)

    • Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention.
    • Tindale LC, Zhantuyakova A, Lam S, Woo M, Kwon JS, Hanley GE, Knoppers B, Schrader KA, Peacock SJ, Talhouk A, Dummer T, Metcalfe K, Pashayan N, Foulkes WD, Manchanda R, Huntsman D, Stuart G, Simard J, Dawson L.
    • Curr Oncol. 2022 Jun 30;29(7):4632-4646. doi: 10.3390/curroncol29070368.
    • Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China.
    • Sun L, Cui B, Wei X, Sadique Z, Yang L, Manchanda R, Legood R.
    • Cancers (Basel). 2022 Apr 6;14(7):1839. doi: 10.3390/cancers14071839.
    • Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?
    • Jakuboski SH, McDonald JA, Terry MB.
    • NPJ Breast Cancer. 2022 Mar 22;8(1):36. doi: 10.1038/s41523-022-00391-4.
    • A systematic review of the methodological quality of economic evaluations in genetic screening and testing for monogenic disorders.
    • Johnson K, Saylor K, Guynn I, Hicklin K, Berg JS, Lich KH.
    • Genet Med. 2022 Feb;24(2):262-288. doi: 10.1016/j.gim.2021.10.008. Epub 2021 Dec 7.
    • Special Issue “Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer”.
    • Manchanda R.
    • Cancers (Basel). 2022 Jan 10;14(2):319. doi: 10.3390/cancers14020319.
    • Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs.
    • Perkins AT, Haslem D, Goldsberry J, Shortt K, Sittig L, Raghunath S, Giauque C, Snow S, Fulde G, Moulton B, Jones D, Nadauld L.
    • Cancers (Basel). 2021 Nov 10;13(22):5612. doi: 10.3390/cancers13225612.
    • Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
    • Ji G, Bao L, Yao Q, Zhang J, Zhu X, Bai Q, Shao Z, Yang W, Zhou X.
    • J Cancer Res Clin Oncol. 2021 Oct;147(10):2935-2944. doi: 10.1007/s00432-021-03696-2. Epub 2021 Jul 13.
    • Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    • Simões Corrêa Galendi J, Vennedey V, Kentenich H, Stock S, Müller D.
    • Cancers (Basel). 2021 Sep 29;13(19):4879. doi: 10.3390/cancers13194879.
    • Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations.
    • Meshkani Z, Aboutorabi A, Moradi N, Langarizadeh M, Motlagh AG.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):35. doi: 10.1186/s13053-021-00191-0.
    • A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer.
    • Carbonara N, La Forgia D, Pellegrino R, Ressa C, Tommasi S.
    • J Pers Med. 2021 Aug 27;11(9):847. doi: 10.3390/jpm11090847.
    • Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives.
    • Ficarazzi F, Vecchi M, Ferrari M, Pierotti MA.
    • Breast. 2021 Aug;58:121-129. doi: 10.1016/j.breast.2021.04.011. Epub 2021 May 12.
    • Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings.
    • Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA.
    • J Genet Couns. 2021 Jul 7. doi: 10.1002/jgc4.1459. Epub ahead of print.
    • Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
    • Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA.
    • Am J Obstet Gynecol. 2021 Jul;225(1):68.e1-68.e11. doi: 10.1016/j.ajog.2021.01.029. Epub 2021 Feb 4.
    • A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis.
    • Katki HA, Bebu I.
    • J R Stat Soc Ser A Stat Soc. 2021 Jul;184(3):887-903. doi: 10.1111/rssa.12680. Epub 2021 Mar 23.
    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).
    • Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J.
    • J Pers Med. 2021 Jun 4;11(6):511. doi: 10.3390/jpm11060511.
    • Out-of-pocket and private pay in clinical genetic testing: a scoping review.
    • Grant P, Langlois S, Lynd LD; GenCOUNSEL Study, Austin JC, Elliott AM.
    • Clin Genet. 2021 Jun 3. doi: 10.1111/cge.14006. Epub ahead of print.
    • Review
    • Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer.
    • Cheng LJ, Wong G, Chay WY, Ngeow J, Tan Y, Soon SS, Aziz MIA, Pearce F, Ng K.
    • Expert Rev Pharmacoecon Outcomes Res. 2021 Feb 16. doi: 10.1080/14737167.2021.1890587. Epub ahead of print.
    • Downstream Revenue Generated by a Cancer Genetic Counselor.
    • Mauer CB, Reys BD, Hall RE, Campbell CL, Pirzadeh-Miller SM.
    • JCO Oncol Pract. 2021 Feb 8:OP2000464. doi: 10.1200/OP.20.00464. Epub ahead of print.
    • Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
    • Koldehoff A, Danner M, Civello D, Rhiem K, Stock S, Müller D.
    • Value Health. 2021 Feb;24(2):303-312. doi: 10.1016/j.jval.2020.09.016. Epub 2021 Jan 5.
    • Review
    • Economic impact of multigene panel testing for hereditary breast and ovarian cancer.
    • Byfield SD, Wei H, DuCharme M, Lancaster JM.
    • J Comp Eff Res. 2021 Jan 25. doi: 10.2217/cer-2020-0192. Epub ahead of print.
    • Estimation of healthcare-related charges in women with BRCA mutations and breast cancer.
    • Biskupiak J, Unni S, Telford C, Yoo M, Ye X, Deka R, Brixner D, Stenehjem D.
    • BMC Health Serv Res. 2021 Jan 13;21(1):58. doi: 10.1186/s12913-020-06038-z.
    • Cost effectiveness of whole population BRCA genetic screening for cancer prevention in Israel.
    • Michaan N, Leshno M, Safra T, Sonnenblick A, Laskov I, Grisaru D.
    • Cancer Prev Res (Phila). 2020 Dec 22:canprevres.0411.2020. doi: 10.1158/1940-6207.CAPR-20-0411. Epub ahead of print.
    • Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.
    • Printz C.
    • Cancer. 2020 Dec 1;126(23):5007. doi: 10.1002/cncr.33302.

    Related:

    Original research:

    Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.

    • Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.
    • Qin Z, Kuok CN, Dong H, Jiang L, Zhang L, Guo M, Leong HK, Wang L, Meng G, Wang SM.
    • J Med Genet. 2020 Aug 17:jmedgenet-2020-107181. doi: 10.1136/jmedgenet-2020-107181. Epub ahead of print.
    • Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
    • Grzymski JJ, Elhanan G, Morales Rosado JA, Smith E, Schlauch KA, Read R, Rowan C, Slotnick N, Dabe S, Metcalf WJ, Lipp B, Reed H, Sharma L, Levin E, Kao J, Rashkin M, Bowes J, Dunaway K, Slonim A, Washington N, Ferber M, Bolze A, Lu JT.
    • Nat Med. 2020 Jul 27. doi: 10.1038/s41591-020-0982-5. Epub ahead of print.
    • Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.
    • Manchanda R, Sun L, Patel S, Evans O, Wilschut J, De Freitas Lopes AC, Gaba F, Brentnall A, Duffy S, Cui B, Coelho De Soarez P, Husain Z, Hopper J, Sadique Z, Mukhopadhyay A, Yang L, Berkhof J, Legood R.
    • Cancers (Basel). 2020 Jul 17;12(7):1929. doi: 10.3390/cancers12071929.

    Related:

    Press: BRCA1/2 Population Screening Predicted to be Cost-Effective in Countries With Different Income Levels (GenomeWeb)

    Commentary:

    Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.

    • Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
    • Simoes Correa-Galendi J, Del Pilar Estevez Diz M, Stock S, Müller D.
    • Appl Health Econ Health Policy. 2020 Jun 15. doi: 10.1007/s40258-020-00599-0. Epub ahead of print
    • Genetic testing costs and compliance with clinical best practices.
    • Montanez K, Berninger T, Willis M, Harding A, Lutgendorf MA.
    • J Genet Couns. 2020 May 1. doi: 10.1002/jgc4.1285. [Epub ahead of print]
    • Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic.
    • Hallquist MLG, Tricou EP, Hallquist MN, Savatt JM, Rocha H, Evans AE, Deckard N, Hu Y, Kirchner HL, Pervola J, Rahm AK, Rashkin M, Schmidlen TJ, Schwartz MLB, Williams JL, Williams MS, Buchanan AH.
    • Genet Med. 2020 Apr 30. doi: 10.1038/s41436-020-0797-2. Epub ahead of print.
    • Analisi di minimizzazione dei costi di una strategia di test preventivo per le familiari di pazienti con carcinoma dell’ovaio BRCA mutato [A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer].
    • Brino ED, Ruggeri M, Boccia S, Cerana N, Lorusso D, Sacchini D, Savarese A, Varesco L, Cicchetti A.
    • Glob Reg Health Technol Assess. 2020 Apr 4;7:1-8. Italian. doi: 10.33393/grhta.2020.557.
    • Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing.
    • Versel N.
    • GenomeWeb. 2020 Apr 3.
    • News
    • Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    • Hurry M, Eccleston A, Dyer M, Hoskins P
    • Int J Technol Assess Health Care. 2020 Apr;36(2):104-112. doi: 10.1017/S0266462319003519.
    • Future Research Suggestions for Multigene Testing in Unselected Populations.
    • Jun I, Berger AL, Yaghjyan L.
    • JAMA Oncol. 2020 Mar 26. doi: 10.1001/jamaoncol.2020.0128. [Epub ahead of print]
    • Letter, Comment

    Related:

    Original research:

    A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.

    Letter, Reply:

    Future Research Suggestions for Multigene Testing in Unselected Populations-Reply.

    • Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
    • Lipton JH, Zargar M, Warner E, Greenblatt EE, Lee E, Chan KKW, Wong WWL.
    • Hum Reprod. 2020 Feb 29;35(2):434-445. doi: 10.1093/humrep/dez203.
    • Testing for Breast Cancer Susceptibility Genes.
    • Mangione C, Manchanda R.
    • JAMA Oncology. JN Learning. 2020 Feb 11.
    • Podcast. CME activity.
    • Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
    • Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR.
    • J Pers Med. 2020 Feb 3;10(1). pii: E7. doi: 10.3390/jpm10010007.
    • A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    • Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print]

    Related:

    CME Audio Interview: Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer. (JN Learning : JAMA Oncology)

    Press: Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients. (GenomeWeb)

    Letter, Comment:

    Future Research Suggestions for Multigene Testing in Unselected Populations.

    Letter, Reply:

    Future Research Suggestions for Multigene Testing in Unselected Populations—Reply.

    • The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance.
    • Neusser S, Lux B, Barth C, Pahmeier K, Rhiem K, Schmutzler R, Engel C, Wasem J, Neumann A.
    • Curr Med Res Opin. 2019 Aug 8:1. doi: 10.1080/03007995.2019.1654689. [Epub ahead of print]
    • Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.
    • Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP.
    • Front Pharmacol. 2019 Aug 2;10:830. doi: 10.3389/fphar.2019.00830. eCollection 2019.
    • Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    • Moya-Alarcón C, González-Domínguez A, Simon S, Pérez-Román I, González-Martín A, Bayo-Lozano E, Sánchez-Heras AB.
    • Clin Transl Oncol. 2019 Aug;21(8):1076-1084. doi: 10.1007/s12094-018-02026-2. Epub 2019 Jan 8.
    • Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction.
    • Dayan E, Chittenden A, Garber JE, Wo L, Caterson SA, Carty MJ, Erdmann-Sager J.
    • Plast Reconstr Surg. 2019 Jul;144(1):12-20. doi: 10.1097/PRS.0000000000005693.
    • A cost-effectiveness analysis of universal genetic testing for common hereditary cancer mutations in women compared with family-history based testing.
    • Drummey AB, Brown J, Drury L, Amacker-North L, Warsinske K, Tyrie K, Naumann RW.
    • Gynecol Oncol. 2019 Jun;153(3):e20. doi: 10.1016/j.ygyno.2019.03.152.
    • Conference abstract
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    • Mariotto A, Jayasekerea J, Petkov V, Schechter CB, Enewold L, Helzlsouer KJ, Feuer EJ, Mandelblatt JS.
    • J Natl Cancer Inst. 2019 Apr 24. pii: djz068. doi: 10.1093/jnci/djz068. [Epub ahead of print]
    • Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
    • Tutty E, Petelin L, McKinley J, Young MA, Meiser B, Rasmussen VM, Forbes Shepherd R, James PA, Forrest LE.
    • Eur J Hum Genet. 2019 Apr 8. doi: 10.1038/s41431-019-0390-9. [Epub ahead of print]
    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    • Kwon JS, Tinker AV, Hanley GE, Pansegrau G, Sun S, Carey MS, Schrader I.
    • Gynecol Oncol. 2019 Mar;152(3):459-464. doi: 10.1016/j.ygyno.2018.10.014.
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    • Müller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, Stock S, Rhiem K.
    • Eur J Health Econ. 2019 Feb 21. doi: 10.1007/s10198-019-01038-1. [Epub ahead of print]
    • Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.
    • Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, Amor DJ, Huq A, Petelin L, Nelson M, James PA, Winship I, McNeil JJ, Lacaze P.
    • Genet Med. 2019 Feb 18. doi: 10.1038/s41436-019-0457-6. [Epub ahead of print]
    • The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway.
    • Asphaug L, Melberg HO.
    • MDM Policy Pract. 2019 Feb 1;4(1):2381468318821103. doi: 10.1177/2381468318821103. eCollection 2019 Jan-Jun.
    • A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.
    • Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA.
    • Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):293-302. doi: 10.1158/1055-9965.EPI-18-0584. Epub 2019 Jan 28.
    • Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.
    • Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis PO, Kohler C, Erlanger TE, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse LL, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands EJG, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi MC; for the CASCADE Consortium.
    • Public Health Genomics. 2019 Jan 29:1-12. doi: 10.1159/000496495. [Epub ahead of print]
    • Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    • Hoskins P, Eccleston A, Hurry M, Dyer M.
    • Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061-7. doi: 10.1016/j.ygyno.2019.01.018. [Epub ahead of print]
    • Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom.
    • Autier P.
    • JAMA Oncol. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6501. [Epub ahead of print]
    • Letter, Comment

    Related:

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply.

    Original research:

    Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

    • Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.
    • Nielsen SM, De Simone LM, Olopade OI.
    • J Genet Couns. 2018 Dec;27(6):1405-1410. doi: 10.1007/s10897-018-0269-x. Epub 2018 Jun 26.
    • Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation.
    • Ramos MCA, Folgueira MAAK, Maistro S, Campolina AG, Soárez PC, Bock GH, Novaes HMD, Diz MDPE.
    • Rev Saude Publica. 2018 Nov 29;52:94. doi: 10.11606/S1518-8787.2018052000643.
    • Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
    • Pashayan N, Morris S, Gilbert FJ, Pharoah PDP.
    • JAMA Oncol. 2018 Nov 1;4(11):1504-1510. doi: 10.1001/jamaoncol.2018.1901.

    Related:

    Editorial:

    Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine.

    Audio Interview: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening. (JAMA Oncology)

    Press: Breast Cancer Screening Only for Women at Higher Risk. (Medscape)

    Letter, Comment:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom—Reply.

    • Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
    • Kinney AY, Howell R, Ruckman R, McDougall JA, Boyce TW, Vicuña B, Lee JH, Guest DD, Rycroft R, Valverde PA, Gallegos KM, Meisner A, Wiggins CL, Stroup A, Paddock LE, Walters ST.
    • Contemp Clin Trials. 2018 Oct;73:123-135. doi: 10.1016/j.cct.2018.09.005. Epub 2018 Sep 18.
    • Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
    • Petelin L, James PA, Trainer AH.
    • Intern Med J. 2018 Oct;48(10):1269-1272. doi: 10.1111/imj.14058.
    • Commentary, Review
    • Population based germline testing for primary cancer prevention.
    • Manchanda R, Legood R.
    • Oncotarget. 2018 Sep 4;9(69):33062-33063. eCollection 2018 Sep 4.

    Related:

    Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.

    • Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
    • Tuffaha HW, Mitchell A, Ward RL, Connelly L, Butler JRG, Norris S, Scuffham PA.
    • Genet Med. 2018 Sep;20(9):985-994. doi: 10.1038/gim.2017.231. Epub 2018 Jan 4.
    • Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    • Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, Hopper JL, MacInnis RJ, Turnbull C, Ramus SJ, Gayther SA, Pharoah PDP, Menon U, Jacobs I, Legood R.
    • J Natl Cancer Inst. 2018 Jul 1;110(7):714-725. doi: 10.1093/jnci/djx265.

    Related:

    Editorial:

    Population Testing for High Penetrance Genes: Are We There Yet?

    Commentary:

    Population based germline testing for primary cancer prevention.

    • Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    • Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, Hopper JL, MacInnis RJ, Turnbull C, Ramus SJ, Gayther SA, Pharoah PDP, Menon U, Jacobs I, Legood R.
    • J Natl Cancer Inst. 2018 Jul 1;110(7):714-725. doi: 10.1093/jnci/djx265.

    Related:

    Editorial:

    Population Testing for High Penetrance Genes: Are We There Yet?

    • Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.
    • Petelin L, Liew D, Mitchell G, James PA, Trainer AH.
    • Value Health. 2018 Jul;21(7):891-893. doi: 10.1016/j.jval.2018.02.009. Epub 2018 May 16.
    • Letter

    Related:

    A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

    Letter:

    A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.

    • A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.
    • Li Y, Devlin JJ.
    • Value Health. 2018 Jul;21(7):893-894. doi: 10.1016/j.jval.2018.02.010. Epub 2018 Apr 5.
    • Letter

    Related:

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Original Research:

    A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

    • Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
    • Lim KK, Yoon SY, Mohd Taib NA, Shabaruddin FH, Dahlui M, Woo YL, Thong MK, Teo SH, Chaiyakunapruk N.
    • Appl Health Econ Health Policy. 2018 Jun;16(3):395-406. doi: 10.1007/s40258-018-0384-8.
    • Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.
    • Delgado-Ortega L, Ginés Rubió J, Garcías de España MDC, Carcedo D, Cordero Puentes L, Moya de Alarcón C.
    • Farm Hosp. 2018 May 1;42(3):95-102. doi: 10.7399/fh.10904.
    • BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer.
    • Norum J, Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Undlien DE, Schlichting E, Mæhle L.
    • ESMO Open. 2018 Apr 13;3(3):e000328. doi: 10.1136/esmoopen-2018-000328. eCollection 2018.
    • Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    • Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans G, Hopper J, Macinnis RJ, Menon U, Jacobs I, Legood R.
    • Am J Obstet Gynecol. 2017 Nov;217(5):578.e1-578.e12. doi: 10.1016/j.ajog.2017.06.038. Epub 2017 Jul 6.
    • Cancer Status Bests Family History for BRCA Testing.
    • Neil Osterweil.
    • Medscape. Conference News. 2017 Oct 19.
    • Optimization of quality assurance to increase clinical utility and cost effectiveness of hereditary cancer testing.
    • Smith S, Marino I, Schaller J, Arnell C, Moyes K, Manley S.
    • Per Med. 2017 May;14(3):213-220. doi: 10.2217/pme-2016-0091. Epub 2017 Mar 29.
    • The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use.
    • Roberts MC, Dusetzina SB.
    • J Community Genet. 2017 Apr;8(2):141-146. doi: 10.1007/s12687-017-0295-7. Epub 2017 Mar 15.
    • A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    • Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ.
    • Value Health. 2017 Apr;20(4):547-555. doi: 10.1016/j.jval.2017.01.006. Epub 2017 Feb 23.

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Letter:

    A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.

    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    • Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.
    • Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.
    • The Impact of an Expanded Genetic Testing Program and Selective Oophorectomy on the Incidence of Ovarian Cancer in West Pomerania.
    • Menkiszak J, Sopik V, Chudecka-Głaz A, Domagała W, Urasińska E, Symonowicz H, Majdanik E, Waloszczyk P, Sycz K, Świniarska M, Huzarski T, Cybulski C, Debniak T, Oszurek O, Lubinski J, Narod SA, Gronwald J.
    • Clin Genet. 2017 Feb;91(2):322-327. doi: 10.1111/cge.12865. Epub 2016 Oct 19.
    • Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.
    • Foote JR, Lopez-Acevedo M, Buchanan AH, Secord AA, Lee PS, Fountain C, Myers ER, Cohn DE, Reed SD, Havrilesky LJ.
    • J Oncol Pract. 2017 Feb;13(2):e120-e129. doi: 10.1200/JOP.2016.011866. Epub 2017 Jan 3.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Always Handy

    • Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
    • D'Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, Villari P.
    • Genet Med. 2016 Dec;18(12):1171-1180. doi: 10.1038/gim.2016.29. Epub 2016 Apr 14.
    • A collaborative approach to cancer risk assessment services using genetic counselor extenders in a multi-system community hospital.
    • Cohen SA, Nixon DM.
    • Breast Cancer Res Treat. 2016 Oct;159(3):527-34. doi: 10.1007/s10549-016-3964-z. Epub 2016 Aug 31.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Assist physicians with ordering testing?

    • Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study.
    • Evans DG, Astley S, Stavrinos P, Harkness E, Donnelly LS, Dawe S, Jacob I, Harvie M, Cuzick J, Brentnall A, Wilson M, Harrison F, Payne K, Howell A.
    • Southampton (UK): NIHR Journals Library; 2016 Aug.
    • Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
    • George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, Rahman N.
    • Sci Rep. 2016 Jul 13;6:29506. doi: 10.1038/srep29506.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Are We Just A Bunch of Health Care Money-Wasters Who Are Indirectly Responsible For People Getting Preventable Cancers?

    News:

    Streamlined genetic testing pathway is developed for women with ovarian cancer.

    Press: Simplified the Process. (GenomeWeb)

    Press: All women with ovarian cancer should be offered genetic testing – so why aren’t they? (Science Blog)

    • A cost analysis of a cancer genetic service model in the UK.
    • Slade I, Hanson H, George A, Kohut K, Strydom A, Wordsworth S, Rahman N; MCG programme.
    • J Community Genet. 2016 Jul;7(3):185-94. doi: 10.1007/s12687-016-0266-4. Epub 2016 Feb 27.
    • [Latest international guidelines for screening, prevention and treatment of familial breast cancer - implications for the relevant practice in Hungary].
    • Romics L, Kocsis J, Ormándi K, Molnár BÁ.
    • Orv Hetil. 2016 Jul;157(28):1117-25. doi: 10.1556/650.2016.30473.
    • Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making.
    • Long EF, Ganz PA.
    • JAMA Oncol. 2015 Dec 1;1(9):1217-1218. doi: 10.1001/jamaoncol.2015.2340.

    Related:

    News: Costs of Universal BRCA1/BRCA2 Testing May Exceed Benefits (Clinical OMICs)

    • Cost-Effectiveness Analysis of Testing for Brca1 and Brca2 Mutations In Women Diagnosed With Ovarian Cancer and Their Female First- And Second Degree Relatives Using A Discrete Event Simulation: A Uk Health Service Perspective.
    • Eccleston A, Bentley A, Dyer M, Vereecken W, George A, Rahman .
    • Value Health. 2015 Nov;18(7):A361. doi: 10.1016/j.jval.2015.09.697. Epub 2015 Oct 20.
    • Genetic testing and economic evaluations: a systematic review of the literature.
    • D'Andrea E, Marzuillo C, Pelone F, De Vito C, Villari P.
    • Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):45-50.
    • Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    • Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.
    • J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

    Related:

    Press: Current way of detecting gene mutations misses people at high risk of cancer. (Medical Xpress)

    Press: Population Genetic Testing Favored for BRCA1/BRCA2 Mutations in Ashkenazi-Jewish Women. (Medscape / Reuters Health)

    • Precision medicine meets public health: population screening for BRCA1 and BRCA2.
    • Levy-Lahad E, Lahad A, King MC.
    • J Natl Cancer Inst. 2014 Dec 30;107(1):420. doi: 10.1093/jnci/dju420. Print 2015 Jan.

    Related:

    Press: Precision Medicine Meets Public Health: Population Screening for BRCA1 and BRCA2. (Medscape)

    • Cost-Effectiveness Analysis of Testing for Brca Mutations in Women Diagnosed with Ovarian Cancer and their Female First-Degree Relatives: A Uk Health Service Perspective.
    • Dyer M, Vereecken W, Worrall J, George A, Rahman N.
    • Value Health. 2014 Nov;17(7):A643-4. doi: 10.1016/j.jval.2014.08.2327. Epub 2014 Oct 26.
    • Conference abstract
    • Cost Effectiveness Analysis of Genetic Testing for Breast and Ovarian Cancer Susceptibility Genes: BRCA1 and BRCA2.
    • Kaldate R, Huston A, McCoy H, Cardeiro D, Noyes K.
    • Breast J. 2014 May;20(3):325-6. doi: 10.1111/tbj.12269. Epub 2014 Apr 8.
    • Letter
    • Economics of genomic testing for women with breast cancer.
    • Lieberthal RD.
    • Am J Manag Care. 2013 Dec;19(12):1024-31.
    • Cost-effectiveness of a genetic test for breast cancer risk.
    • Folse HJ, Green LE, Kress A, Allman R, Dinh TA.
    • Cancer Prev Res (Phila). 2013 Dec;6(12):1328-36. doi: 10.1158/1940-6207.CAPR-13-0056.

    Related:

    Comment/Letter:

    Cost-effectiveness of a genetic test for breast cancer risk--letter.

    Comment/Letter:

    Cost-effectiveness of a genetic test for breast cancer risk--response.

    • Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.
    • Feliubadaló L, Lopez-Doriga A, Castellsagué E, Del Valle J, Menéndez M, Tornero E, Montes E, Cuesta R, Gómez C, Campos O, Pineda M, González S, Moreno V, Brunet J, Blanco I, Serra E, Capellá G, Lázaro C.
    • Eur J Hum Genet. 2013 Aug;21(8):864-70. doi: 10.1038/ejhg.2012.270. Epub 2012 Dec 19.

    Related:

    Press: The Future of BRCA1/BRCA2 Testing. (OncLive)

    • Developing national guidance on genetic testing for breast cancer predisposition: the role of economic evidence?
    • Sullivan W, Evans DG, Newman WG, Ramsden SC, Scheffer H, Payne K.
    • Genet Test Mol Biomarkers. 2012 Jun;16(6):580-91. doi: 10.1089/gtmb.2011.0236. Epub 2012 Feb 7.
    • BRCA1/2 genetic testing found cost-effective in current era.
    • Goodman A.
    • Am J Manag Care. 2012 May;18(3 Spec No.):SP133.